R
RTW Investments, LP
+ HältZLAB
-11.31%
3-Monats-Rendite
$23.190
-0.315 (-1.36%)Zum Schluss
Loading chart…
- Hoch
- 24.640
- Eröffnung
- 24.550
- Volumengewichteter Durchschnittskurs
- 23.66
- Volumen
- 843.23K
- Marktkap.
- 1.73B
- Tief
- 23.140
- Umsatz
- 19.95M
- EV/EBITDA, TTM
- -6.11
Zai Lab Ltd is a holding company primarily engaged in biopharmaceutical business. The Company is focused on discovering, developing, and commercializing products that address medical conditions with significant unmet needs in the areas of oncology, immunology, neuroscience, and infectious disease. The Company has a series of patented drug candidates from the discovery stage to the late clinical project, including ZEJULA, OPTUNE, QINLOCK, NUZYRA and VYVGART, and others. The Company conducts its businesses within domestic and overseas markets.
KI-Analyse of Zai Lab Ltd (ZLAB)
HaltenZai Lab Ltd is currently priced at $24.99, which is below the average analyst price target of $40.50, indicating potential upside. However, the stock has a low RSI of 43.54, suggesting it is nearing oversold conditions, but the recent insider selling has increased by 126%, which raises concerns about the stock's short-term stability.
Analystenbewertungen (3)
+106.68% Aufwärtspotenzial
Kaufen
2 Kaufen
1 Halten
0 Verkaufen
Aktuell: 23.19
Tief
25.70
Durchschnitt
47.93
Hoch
74.00
JPMorgan
Übergewichten
$36
2026-08-27
JPMorgan
2026-08-27
Kursziel
$36
Übergewichten
Citi
Kaufen
$45
2026-08-07
Citi
2026-08-07
Kursziel
$45
Kaufen
Citi
Kaufen
$44
2026-05-08
Citi
2026-05-08
Kursziel
$44
Kaufen
JPMorgan
Übergewichten
$32
2026-03-18
JPMorgan
2026-03-18
Kursziel
$32
Übergewichten
Cantor Fitzgerald
Übergewichten
$37
2026-02-27
Cantor Fitzgerald
2026-02-27
Kursziel
$37
Übergewichten
Bewertungskennzahlen
Das aktuelle erwartete KGV von Zai Lab Ltd (ZLAB) beträgt 0.00, verglichen mit dem 5-Jahres-Durchschnitt von -16.19.
Whales, die ZLAB halten
Event-Zeitleiste
News
9.010-14NewsfilterZai Lab to Present ZL-1503 Clinical Trial Data at ACAAI 2026
9.509-17CNBCChinese AI Companies Struggle with Revenue Growth
- 8.509-17Newsfilter
Chinese AI Models Generate Only 10% of Revenue Compared to U.S. Rivals
8.509-14CNBCZ.ai Plans to Raise $5 Billion Through Share Placement and Bonds
- 8.509-14Newsfilter
Z.ai Plans $5 Billion Fundraising, Shares Plunge Over 10%
ZLAB FAQ – beantwortet von Alphio AI
Zai Lab Ltd is a holding company primarily engaged in biopharmaceutical business. The Company is focused on discovering, developing, and commercializing products that address medical conditions with significant unmet needs in the areas of oncology, immunology, neuroscience, and infectious disease. The Company has a series of patented drug candidates from the discovery stage to the late clinical project, including ZEJULA, OPTUNE, QINLOCK, NUZYRA and VYVGART, and others. The Company conducts its businesses within domestic and overseas markets. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).
Zai Lab Ltd is currently priced at $24.99, which is below the average analyst price target of $40.50, indicating potential upside. However, the stock has a low RSI of 43.54, suggesting it is nearing oversold conditions, but the recent insider selling has increased by 126%, which raises concerns about the stock's short-term stability.
3 analysts cover ZLAB: 2 rate it Buy, 1 Hold and 0 Sell. The average price target is 47.93.
Community
Mehr ↗Noch keine Beiträge
Registriere dich oder melde dich an, um mitzudiskutierenDiese Seite dient nur der Recherche und ist keine Anlageberatung. Modelle können falsch liegen. Vergangene Wertentwicklung ist kein Indikator für die Zukunft.